Investigational drug · Phase 2
IPN60300
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced Solid Tumor, Metastatic Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IPN60300"
First trial start
2025
Dec 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IPN60300", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "IPN60300" as an intervention, largest first.
- A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursPivotal-lookingRecruiting
IpsenIndustry
NCT07213817 · 114 participants (planned) · Start Dec 5, 2025 · Primary completion Oct 30, 2028
Drug: IPN60300 · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: New Haven, Connecticut; Grand Rapids, Michigan; Philadelphia, Pennsylvania · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Locally Advanced Solid Tumor
- NeladalkibNVL-655Phase 32 trials
Nuvalent Inc. · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive, Locally Advanced Solid Tumor
- VC004Phase 31 trial
Jiangsu vcare pharmaceutical technology co., LTD · Locally Advanced Solid Tumor
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
- FMC-376Phase 22 trials
Frontier Medicines Corporation · Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor
- FMC-242Phase 21 trial
Frontier Medicines Corporation · Locally Advanced Solid Tumor
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- TST003Phase 21 trial
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- YH32364Phase 21 trial
Yuhan Corporation · EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.